Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Assets (2016 - 2025)

Historic Current Assets for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $93.6 million.

  • Niagen Bioscience's Current Assets rose 7956.8% to $93.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.6 million, marking a year-over-year increase of 7956.8%. This contributed to the annual value of $64.1 million for FY2024, which is 2941.01% up from last year.
  • Per Niagen Bioscience's latest filing, its Current Assets stood at $93.6 million for Q3 2025, which was up 7956.8% from $86.7 million recorded in Q2 2025.
  • Niagen Bioscience's Current Assets' 5-year high stood at $93.6 million during Q3 2025, with a 5-year trough of $37.9 million in Q3 2022.
  • In the last 5 years, Niagen Bioscience's Current Assets had a median value of $49.1 million in 2024 and averaged $54.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 3352.9% in 2022, then skyrocketed by 7956.8% in 2025.
  • Over the past 5 years, Niagen Bioscience's Current Assets (Quarter) stood at $48.9 million in 2021, then dropped by 4.78% to $46.6 million in 2022, then rose by 6.37% to $49.5 million in 2023, then grew by 29.41% to $64.1 million in 2024, then soared by 46.04% to $93.6 million in 2025.
  • Its Current Assets was $93.6 million in Q3 2025, compared to $86.7 million in Q2 2025 and $76.2 million in Q1 2025.